Is DRUG undervalued? Our fair value estimate
Bright Minds Biosciences Inc. · Healthcare · NCM
How we got here
The estimate is computed from DRUG's reported fundamentals, with a growth assumption that is deliberately capped: small changes to an uncapped growth or terminal assumption can justify any price, and a number that can justify anything means nothing. These are the inputs the model holds for DRUG today; the exact method, and where it goes wrong, is on the methodology page.
Wall Street's published earnings growth forecast, used as context for the capped growth assumption, never swallowed whole.
Persistent high returns on capital are what a moat looks like in the accounts, and they feed the moat score alongside the valuation.
A volatility measure against the wider market. A jumpier share earns a larger discount for risk, which lowers the estimate.
Wall Street's number, next to ours
The mean analyst price target for DRUG is USD167.60 across 3 analysts, which implies +124.6% from the current price. Our estimate is USD30.45. They answer different questions: an analyst target is a 12-month price prediction averaged across banks; ours is a model's view of what the business is worth, with every assumption published. When they disagree, at least one of us is wrong.
The belief gap: what growth this price asks you to believe
Run our DCF backwards and every price becomes a growth assumption. One axis compares them: today's market price, the entry prices implied by super investors' 13F filings, the mean analyst target, and the growth our own model funds. The gap between the market's marker and the cohort's markers is the growth you are being asked to believe that informed buyers did not need.
Today's price asks you to believe about 27.5% annual cash-flow growth. Millennium Management's Q4 2025 entry underwrote a higher 28.7%. Our model funds 5.0%.
Millennium Management's Q4 2025 filing implies an average entry near $78.04, which implied about 28.7% annual growth under our model (low confidence).
D. E. Shaw &'s Q1 2026 filing implies an average entry near $72.97, which implied about 26.9% annual growth under our model.
Marshall Wace's Q4 2025 filing implies an average entry near $78.04, which implied about 28.7% annual growth under our model (low confidence).
Two Sigma Investments's Q4 2025 filing implies an average entry near $78.04, which implied about 28.7% annual growth under our model (low confidence).
Entry prices are filing-implied averages (reported position value divided by reported shares for the quarter a position was opened or materially increased), not actual cost bases; 13Fs lag by up to 45 days. How the Belief Gap is computed.
Healthcare peers, by our rating
The same model, run on the highest-rated names in the same sector. A gap to fair value is only comparable when the method behind it is identical, which here it is.
Common questions
Is Bright Minds Biosciences Inc. (DRUG) undervalued?
On our model, DRUG at USD74.61 trades 59% above our fair value estimate of USD30.45, so it screens as overvalued today. That is one model's answer, not a recommendation: a fair value estimate is an argument about the future, and the market is frequently right about why something is cheap.
What is the fair value of DRUG?
Our current fair value estimate for Bright Minds Biosciences Inc. is USD30.45 per share. For comparison, the mean Wall Street analyst price target is USD167.60 across 3 analysts; that is their number, computed differently from ours. The estimate moves as prices and fundamentals move.
How is DRUG's fair value calculated?
From Bright Minds Biosciences Inc.'s reported fundamentals: earnings power, a deliberately capped growth assumption, and a discount for balance sheet and volatility risk. The full method, including its known weaknesses, is published on our methodology page, and the interactive Valuation Lab lets you change every assumption and watch the value move.
Disagree with an assumption? Good. The Valuation Lab on the DRUG app page puts every input of this model on a slider, including a reverse DCF that shows the growth the market is currently pricing in.
A fair value estimate is a model output computed from company filings and market data, refreshed daily; quotes are delayed. It is educational information, not financial advice and not a recommendation to buy or sell anything. Read the full disclaimer.